# Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

> **NCT04700072** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 56 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Pembrolizumab/Quavonlimab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT04700072
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-03
- **Primary completion:** 2025-10-17
- **Final completion:** 2025-10-17
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04700072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04700072, "Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04700072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*